Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06381089
Other study ID # VNS004
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 10, 2024
Est. completion date August 10, 2024

Study information

Verified date April 2024
Source Sinop University
Contact Sefa Haktan HATIK, PhD
Phone 00905058761533
Email haktanhtk@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was conducted in patients with ischemic stroke; This study was conducted to examine the effect of robotic rehabilitation and transcutaneous auricular vagal nerve stimulation applied in addition to robotic rehabilitation on the patient's functional level and autonomic nervous system. 40 people over the age of 18 participated in the study. They were randomly divided into two groups: robotic rehabilitation and transcutaneous auricular vagal nerve stimulation applied in addition to robotic rehabilitation. While the robotic rehabilitation group received Lokomat and neurological rehabilitation, the other group received stimulation with the Vagustim device, which is applied non-invasively through the ear, in addition to Lokomat and neurological rehabilitation. Spasticity, autonomic nervous system, walking speed, motor function, quality of life, muscle activity and pain were evaluated in both groups before starting treatment and six weeks after treatment. In the study, significance was evaluated at p<0.05 level.


Description:

A study group was formed, consisting of individuals who had an ischemic stroke over the age of 18, who complied with the research criteria and who signed the voluntary consent form. Age, gender, height, weight, body mass index, dominant side, affected side and time since stroke of the participants who met the inclusion criteria were recorded and randomly divided into 2 groups. The groups are; They were divided into Robotic Rehabilitation (RRG) (n=20, 11 women, 9 men) and Transcutaneous Auricular Vagal Nerve Stimulation (VRRG) applied in addition to Robotic Rehabilitation (n=20, 9 women, 11 men) groups. A 6-week protocol was applied in the study. In addition to the neurological rehabilitation program, robotic rehabilitation was applied to the RRG group 2 days a week. In addition to the neurological rehabilitation program, both robotic rehabilitation and transcutaneous auricular vagal nerve stimulation were applied to the VRRG group 2 days a week. Some evaluations were made by the researcher at two different time periods throughout the study. Evaluation times; T0 (before robotic rehabilitation/vagal nerve stimulation application in addition to robotic rehabilitation), T1 (robotic rehabilitation/after vagal nerve stimulation application applied in addition to robotic rehabilitation). These time periods were planned and carried out immediately before the study and after 6 weeks of treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date August 10, 2024
Est. primary completion date July 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Being diagnosed with ischemic stroke - Having a stroke for the first time - Having hemiparesis - = 6 months after stroke - Being able to walk with or without support - Understanding and focusing on Lokomat exercises and being able to do them - Having received walking training with Lokomat in our hospital - Having signed the voluntary consent form - Being over 18 years of age Exclusion Criteria: - Body weight more than 135 kg - The person's height is more than two meters - Femur length outside the range of 35-47 cm - Intolerable leg length differences - Peripheral nerve injury - Peripheral neuropathy - Anticholinergic drug use - Presence of skin lesions - Spasticity that prevents the locomotive from working - Having diagnosed psychiatric problems - Severe contracture in lower extremity muscles - Not being able to walk before stroke - Having a history of additional neurological diseases (Parkinson, etc.) - Unstable cardio-pulmonary disease - Having orthopedic fractures (lower extremity fractures) and/or joint implants - Severe osteoporosis - Uncontrolled hypertension despite medication use - Lower extremity amputation

Study Design


Intervention

Device:
Robotic Rehabilitation
Lokomat is an exoskeleton type robotic walking device that can support both extremities symmetrically.
Transcutaneous Auricular Vagal Nerve Stimulation
Vagus nerve stimulation is defined as any technique that stimulates the vagus nerve in our body.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
SEFA HAKTAN HATIK

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Pain Rating Scale Numerical pain scale is used to classify pain from 0 to 10. '0' means no pain and '10' means unbearable pain. Time Frame: within 10 minutes after intervention
Primary Stroke Specific Quality of Life Scale The stroke-specific quality of life scale consists of a total of 49 items in 12 domains. Each item is scored between 1 (strongly agree) and 5 (strongly disagree). The total score is evaluated between 49 and 245 points. A score of 49 indicates the lowest quality of life and 245 indicates the highest quality of life. Time Frame: within 10 minutes after intervention
Primary 10 Meter Walk Test During the test, the patient's walking performance is recorded in terms of time between two markers located 10 meters apart. It is used to determine functional mobility and walking speed. Time Frame: within 10 minutes after intervention
Primary Fugl-Meyer Assessment Lower Extremity It is a widely used scale in the evaluation of motor function after stroke. The lower extremity section consists of 17 items and its maximum score is 34 points. Time Frame: within 10 minutes after intervention
Primary Modified Ashworth Scale It is the universally accepted clinical tool used to measure increases in muscle tone. Time Frame: within 10 minutes after intervention
Primary Electromyography It refers to the collective electrical signals during the contraction of muscles connected to the nervous system. EMG devices evaluate and interpret the electrical potential that enables the contraction of voluntary muscles. The EMG device evaluates voluntarily working skeletal muscles. EMG, a muscle examination, monitors and interprets the electrical activity that causes muscles to contract. EMG examinations are defined as a set of tests that include nerve examination as well as examination of muscle activation. Time Frame: within 10 minutes after intervention
Primary Autonomic Nervous System The Polar H10 device is a gold-standard HRV sensor of high sensitivity and accuracy that comes with a wearable chest strap. The device comes with a soft, adjustable sensor that contacts the chest to capture HRV in real time. Time Frame: within 10 minutes after intervention
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Not yet recruiting NCT01923818 - Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events Phase 2/Phase 3